Welcome to the Funding Opportunities section of the Research Support Center’s website. We understand that securing financial support is essential for advancing groundbreaking research and academic pursuits. To empower our esteemed scholars and researchers, RSC is dedicated to providing a wide array of funding opportunities designed to inspire innovation, foster collaboration, and drive academic excellence. Whether you are embarking on pioneering research projects, seeking educational grants, or aiming to facilitate interdisciplinary partnerships, our funding programs are tailored to meet your diverse needs and aspirations. Explore the numerous avenues we offer to support your research explorations and turn your visionary ideas into impactful realities.
1.Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional)
This Notice of Funding Opportunity (NOFO) aims to support research on interdisciplinary population approaches to increasing awareness of the relationship between alcohol and cancer risk, understanding and changing social norms related to alcohol consumption, developing and/or evaluating alcohol policy approaches, and the development, testing, and implementation of population-level interventions to reduce alcohol-related cancer risk. Applications that address multiple levels of consumption, such as moderate and heavy drinking, are of particular interest, as well as those focusing on alcohol use disorder (AUD) from the perspective of cancer prevention and control. Proposals addressing understudied areas are encouraged, as is attention to underrepresented minority (URM) populations experiencing cancer and alcohol-related disparities such as American Indian, Alaskan Native, and sexual and gender minority populations.
Expiration Date
January 08, 2027
2.Planning for Product Development Strategy (R34 Clinical Trial Not Allowed)
The purpose of this Notice of Funding Opportunity (NOFO) is to support the development of a comprehensive and well-defined product development strategy for next-generation treatments for HIV and HIV-associated comorbidities, coinfections and complications and preventive strategies for HIV, as well as facilitating the translation of research findings into drug products that enables submission of an Investigational New Drug (IND) application to the FDA.
PAR-24-029: Planning for Product Development Strategy (R34 Clinical Trial Not Allowed) (nih.gov)
Expiration Date
December 05, 2026
3.Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31)
The purpose of the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31) award is to enable promising predoctoral students to obtain individualized, mentored research training from outstanding faculty sponsors while conducting dissertation research in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The proposed mentored research training must reflect the candidate’s dissertation research project and is expected to clearly enhance the individual’s potential to develop into a productive, independent research scientist
Expiration Date
September 08, 2025
4.Analytical and Clinical Validation of Biomarkers for Alzheimer’s Disease (AD) and AD-Related Dementias (ADRD) (U01 Clinical Trial Optional)
This notice of funding opportunity (NOFO) invites applications to accelerate the establishment of effective and reliable biomarkers of Alzheimer’s disease (AD) and AD-related dementias (ADRD) for use in therapy/medical product discovery and development, clinical trials, and/or clinical practice. Specifically, this NOFO will support analytical and/or clinical validation of a biomarker, composite biomarker, or biomarker signature, with rigor comparable to the expectations described in the Food and Drug Administration (FDA’s) Biomarker Qualification Program (BQP) or recommended by other FDA regulatory pathways.
Expiration Date
March 06, 2026
5.Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research.
The NCI, through this NOFO encourages submission of projects devoted to demonstrating that mammalian models, including organoids, tumoroids and cell models, used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patient benefit.
Expiration Date
September 08, 2026
6.Device Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional)
The purpose of this notice of funding opportunity (NOFO) is to accelerate the development of devices to treat Substance Use Disorders (SUDs). The continuing advances in technologies offer unprecedented opportunities to develop neuromodulatory or neurophysiological devices that are safe and effective SUD treatments. The objective is to move devices to their next step in the FDA approval process, with the ultimate goal of generating new, FDA approved device-based treatments for SUDs.
Expiration Date
August 14, 2026
7.Engaging Survivors of Sexual Violence and Trafficking in HIV and Substance Use Disorder Services (R34 Clinical Trial Optional)
The goal of this notice of funding opportunity (NOFO) is to support exploratory research and preliminary interventions to address the interrelated and compounding contextual factors that contribute to substance use and HIV risk among survivors of sex trafficking. This would be accomplished through research that builds new interventions and models of care that can effectively engage survivors of sex trafficking in care for substance use disorder (SUD), HIV, trauma, and other mental health outcomes and addresses key structural and social determinants of health that contribute to risk for sexual trafficking, as well as barriers
Expiration Date
August 06, 2024
8. Ruth L. Kirschstein National Research Service Award (NRSA) Individual Senior Fellowship (Parent F33)
The National Institutes of Health (NIH) awards senior individual research training fellowships to experienced scientists who wish to make major changes in the direction of their research careers or who wish to broaden their scientific background by acquiring new research capabilities as independent investigators in research fields relevant to the missions of participating NIH Institutes and Centers.
This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor.
Expiration Date
September 08, 2025.
9.Chimeric Antigen Receptor (CAR) Approaches to AD/ADRD (R61/R33 Clinical Trial Not Allowed)
This Notice of Funding Opportunity (NOFO) aims to provide a proof-of-principle for a novel strategy for Alzheimer’s disease (AD) and AD-related dementias (ADRD) immunotherapies. Specifically, the goal is to examine whether a novel immunotherapeutic approach in cancer immunotherapy with chimeric antigen receptor (CAR) immune cells can be customized as treatments for AD/ADRD.
This NOFO utilizes the R61/R33 Exploratory/Developmental Phased Award activity code. The R61 phase provides up to 2 years of support for initial developmental activities. The R33 phase provides up to 3 years of support for expanded activities.
Expiration Date
February 08, 2024
10.Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for investigator-initiated studies addressing mechanisms by which incretin mimetics, specifically glucagon-like peptide (GLP)-1 or dual GLP-1/ glucose? dependent insulinotropic polypepide (GIP)-1 receptor agonists (RAs), impact cancer risk. The focus on these agents is due to their reported effects on thyroid, prostate and other cancer risks, and the generally more favorable efficacy and side effect profile compared to other classes of incretin mimetics. In addition, this NOFO seeks to draw in talented scientists to the cancer biology field who may study incretin mimetic effects on diseases other than cancer. Investigators wishing to study incretin mimetics other than GLP-1 RAs or GLP-1/GIP-1 RAs, such as dipeptidyl peptidase (DPP)-4 inhibitors, must justify why the agent(s) they propose to study are more effective and/or have a more favorable side effect profile than GLP-1 or GLP-1/GIP-1 RAs. Route of agent administration (oral vs. other) is, by itself, not an adequate justification.
Expiration Date
January 08, 2027
11.Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel Therapeutic Agents for the Spectrum of Alzheimer’s Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
The purpose of this notice of funding opportunity (NOFO) is to invite applications that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline the early-stage evaluation of promising pharmacological interventions for Alzheimer’s disease (AD) and AD-related dementias (ADRD). Candidate interventions evaluated through this program, which can include small molecules or biologics for example, must engage non-amyloid/non-tau mechanisms and aim to address cognitive and/or neuropsychiatric symptoms in individuals across the spectrum, from pre-symptomatic to more severe stages of disease. This NOFO uses a phased award activity code. Applications must include prespecified, go/no-go safety and tolerability milestones that must be met to advance from phase 1 to latter stages of clinical development.
Expiration Date,
November 20, 2026
12.Alcohol Treatment, Pharmacotherapy, and Recovery Research (R34 Clinical Trial required)
The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Required mechanism focusing on alcohol treatment and recovery research. This NOFO will focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD), including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery.
Due date (Expiry date) September 08, 2026
13.Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required)
The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Required mechanism focusing on alcohol treatment and recovery research. This NOFO will focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD), including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery.
Expiration Date
September 08, 2026
14.Alcohol Health Services Research (R01 Clinical Trial Optional)
The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Optional mechanism focusing on alcohol health services. This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations
Expiration Date
September 08, 2026
PAR-23-251: Alcohol Health Services Research (R01 Clinical Trial Optional) (nih.gov)
15.Alcohol Health Services Research (R34 Clinical Trial Optional)
The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Optional mechanism focusing on alcohol health services. This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.
Expiration Date
September 08, 2026
PAR-23-252: Alcohol Health Services Research (R34 Clinical Trial Optional) (nih.gov)
17.Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate translation of scientific discoveries and engineering developments in imaging, data science and/or spectroscopic technologies into methods or tools that address contemporary problems in understanding the fundamental biology, potential risk of development, diagnosis, or treatment of cancer.
Expiration Date
January 08, 2027
18.Elucidating Variability of Physiologic and Functional Responses to Exercise Training in Older Adults (R01 Clinical Trial Required)
The National Institute on Aging (NIA) invites R01 applications that propose human studies to better understand factors underlying response variability to exercise training in older adults through this Notice of Funding Opportunity (NOFO). This NOFO encourages studies that identify systemic modulators, biomarkers, and other potential mechanisms underlying exercise variation in outcomes that are clinically relevant for older adults. Additionally, this NOFO encourages transdisciplinary studies utilizing innovative design methods and analytical approaches combined with clinical phenotyping to disentangle the complicated relationships between endogenous and exogenous factors that drive response variation to exercise. Elucidating factors and mechanisms that underlie variations in exercise response, and the extent to which these factors are modifiable, may enable more precise and efficacious exercise prescriptions to optimize the clinical efficacy of exercise training in older adults.
Expiration Date
November 04, 2023